Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says

MT Newswires Live07-31 23:21

Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.

The company's collaboration with Sanofi (SNY) could become a "more leverageable asset" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.

A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.

The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.

Price: 736.42, Change: -1.92, Percent Change: -0.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655124360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655124360","market":"hk","top_or_hot":-1,"title":"Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.</p><p>The company's collaboration with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.</p><p>A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.</p><p>The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.</p><p>Price: 736.42, Change: -1.92, Percent Change: -0.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-31 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.</p><p>The company's collaboration with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.</p><p>A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.</p><p>The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.</p><p>Price: 736.42, Change: -1.92, Percent Change: -0.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655124360","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655124360","pubTimestamp":1785511282,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron Pharmaceuticals'  robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi  could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: 736.42, Change: -1.92, Percent Change: -0.26","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"加拿大皇家银行表示，再生元制药第二季度销售强劲，支出增长有限，有助于提高下半年利润率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals' (REGN) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.The company's collaboration with Sanofi (SNY) could become a \"more leverageable asset\" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.Price: 736.42, Change: -1.92, Percent Change: -0.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655124360","isCrawlerRequest":true}